| Rochelle Walwer, LCSW | |
|
250 Water Stone Cir, Joliet, IL 60431-8313 | |
| (815) 740-4104 | |
| Not Available |
| Full Name | Rochelle Walwer |
|---|---|
| Gender | Female |
| Speciality | Social Worker - Clinical |
| Location | 250 Water Stone Cir, Joliet, Illinois |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1033595145 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 101Y00000X | Counselor | (* (Not Available)) | Secondary |
| 1041C0700X | Social Worker - Clinical | 149023846 (Illinois) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Rochelle Walwer, LCSW 2733 Midland Dr, Naperville, IL 60564-8975 Ph: (630) 768-2669 | Rochelle Walwer, LCSW 250 Water Stone Cir, Joliet, IL 60431-8313 Ph: (815) 740-4104 |
News Archive
A University of British Columbia and Vancouver Coastal Health Research Institute study has found that a popular class of osteoporosis drugs nearly triples the risk of developing bone necrosis, a condition that can lead to disfigurement and incapacitating pain.
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, together with collaborators at the Massachusetts Institute of Technology (MIT), announced today the publication of new paper describing discovery of "core-shell" nanoparticles for systemic delivery of RNAi therapeutics.
Visual acuity-the ability to discern letters, numbers, and objects from a distance-is essential for many tasks, from recognizing a friend across a room to driving a car.
The combination of preventive medication and behavioral changes offered significant relief for 77 percent of the individuals enrolled in a study aimed at combating frequent, disabling migraine headaches, according to new Ohio University research published this week in the British Medical Journal.
› Verified 4 days ago